相似文献
1
Pharmacotherapy for adults with tumors of the central nervous system.
Pharmacol Ther. 2009 Mar;121(3):253-64. doi: 10.1016/j.pharmthera.2008.11.003. Epub 2008 Nov 27.
2
New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.
Pharmacol Ther. 2009 Apr;122(1):44-55. doi: 10.1016/j.pharmthera.2009.01.001. Epub 2009 Jan 23.
3
Early-stage progress on glioma vaccines.
J Natl Cancer Inst. 2011 Sep 21;103(18):1361-2. doi: 10.1093/jnci/djr363. Epub 2011 Aug 31.
4
[Immunotherapy in brain tumors].
Ann Pathol. 2017 Feb;37(1):117-126. doi: 10.1016/j.annpat.2016.12.001. Epub 2017 Jan 19.
5
Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.
Expert Opin Pharmacother. 2014 Oct;15(14):2047-61. doi: 10.1517/14656566.2014.947266. Epub 2014 Aug 19.
6
Insights into pharmacotherapy of malignant glioma in adults.
Expert Opin Pharmacother. 2009 Oct;10(14):2279-90. doi: 10.1517/14656560903146910.
7
Spinal cord metastasis in a patient treated with bevacizumab for glioblastoma.
Target Oncol. 2013 Jun;8(2):153-5. doi: 10.1007/s11523-013-0270-0. Epub 2013 Feb 21.
8
Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors.
Cancer. 1989 Dec 15;64(12):2420-3. doi: 10.1002/1097-0142(19891215)64:12<2420::aid-cncr2820641204>3.0.co;2-b.
9
Nervous system neoplasms.
Adv Neurol. 2002;90:157-73.
10
Evolving strategies: future treatment of glioblastoma.
Expert Rev Neurother. 2011 Apr;11(4):519-32. doi: 10.1586/ern.11.30.
引用本文的文献
1
Elucidating immunometabolic targets in glioblastoma.
Am J Cancer Res. 2017 Oct 1;7(10):1990-1995. eCollection 2017.
2
Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).
J Neural Transm (Vienna). 2014 May;121(5):469-77. doi: 10.1007/s00702-013-1143-5. Epub 2013 Dec 24.
3
Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.
Ther Deliv. 2010 Aug;1(2):289-305. doi: 10.4155/tde.10.22.
4
Sensitivity to cisplatin in primary cell lines derived from human glioma correlates with levels of EGR-1 expression.
Cancer Cell Int. 2011 Mar 2;11:5. doi: 10.1186/1475-2867-11-5.
5
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.
Curr Gene Ther. 2009 Oct;9(5):409-21. doi: 10.2174/156652309789753301.
本文引用的文献
1
Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update.
Endocr Relat Cancer. 2008 Sep;15(3):721-43. doi: 10.1677/ERC-08-0012.
2
Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas.
Neurology. 2008 Jul 29;71(5):365-73. doi: 10.1212/01.wnl.0000319721.98502.1b.
3
Results of treatment of 112 cases of primary CNS lymphoma.
Jpn J Clin Oncol. 2008 May;38(5):373-80. doi: 10.1093/jjco/hyn027. Epub 2008 Apr 15.
4
Molecular predictors of human nervous system cancer responsiveness to enediyne chemotherapy.
Cancer Chemother Pharmacol. 2008 Sep;62(4):699-706. doi: 10.1007/s00280-008-0725-7. Epub 2008 Mar 13.
5
[Role of MGMT and clinical applications in brain tumours].
Bull Cancer. 2007 Sep;94(9):769-73.
6
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
Neurol Med Chir (Tokyo). 2007 Aug;47(8):341-9; discussion 350. doi: 10.2176/nmc.47.341.
7
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity.
Mol Cancer Ther. 2007 Aug;6(8):2290-302. doi: 10.1158/1535-7163.MCT-07-0062.
8
Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma.
Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12867-72. doi: 10.1073/pnas.0705158104. Epub 2007 Jul 23.
9
Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors.
J Neurochem. 2007 Jul;102(2):522-38. doi: 10.1111/j.1471-4159.2007.04633.x.
10
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
Neurology. 2007 May 22;68(21):1831-6. doi: 10.1212/01.wnl.0000262034.26310.a2.
Zotero 插件